Advanced search×

Fibroblast growth factors and their receptors in cancer.

Biochem J 437(2):199-213 (2011) PMID 21711248

FGFs (fibroblast growth factors) and their receptors (FGFRs) play essential roles in tightly regulating cell proliferation, survival, migration and differentiation during development and adult life. Deregulation of FGFR signalling, on the other hand, has been associated with many developmental syndromes, and with human cancer. In cancer, FGFRs have been found to become overactivated by several mechanisms, including gene amplification, chromosomal translocation and mutations. FGFR alterations are detected in a variety of human cancers, such as breast, bladder, prostate, endometrial and lung cancers, as well as haematological malignancies. Accumulating evidence indicates that FGFs and FGFRs may act in an oncogenic fashion to promote multiple steps of cancer progression by inducing mitogenic and survival signals, as well as promoting epithelial-mesenchymal transition, invasion and tumour angiogenesis. Therapeutic strategies targeting FGFs and FGFRs in human cancer are therefore currently being explored. In the present review we will give an overview of FGF signalling, the main FGFR alterations found in human cancer to date, how they may contribute to specific cancer types and strategies for therapeutic intervention.

DOI: 10.1042/BJ20101603
Version: za2963e q8zae q8zbe q8zcf q8zdd q8ze8 q8zf7 q8zg5

Similar articles you may find interesting…

  1. MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines.

    Oncogene (2013) PMID 23624919

    We do not fully understand how these therapies impact tumor biology, especially given that melanoma is a heterogeneous disease. Using a three-dimensional (3D), collagen-embedded spheroid melanoma model, we observed that MEK and BRAF inhibitors can increase the invasive potential of ∼20% of human m...
  2. Autologous skin reconstruction by combining epidermis and acellular dermal matrix tissue derived from the skin of giant congenital melanocyt...

    J Artif Organs (2013) PMID 23644894

    We tried to produce reconstructed skin by combining the resultant ADM with enzymatically separated GCMN epidermal tissue. The histological structure of the reconstructed skin was examined after it had been cultured for 5 days. In the SDS group, most cells had been removed after 48 h, and the DNA c...
  3. MEK1/2 inhibition decreases lactate in BRAF-driven human cancer cells.

    Cancer Res (2013) PMID 23639941

    We hypothesized that MEK1/2 (MAP2K1/MAP2K2) inhibitors may reduce lactate levels as detected by magnetic resonance spectroscopy (MRS), as a metabolic biomarker for the PD response. MRS was used to monitor intracellular and extracellular levels of lactate in human cancer cells in vitro and in melanom...